2/6/2023 8:18:43 AM
Cyteir Therapeutics Promotes David Gaiero To CFO
11/7/2022 4:27:02 PM
Cyteir Therapeutics Q3 Loss/share $0.31 Vs. Loss $0.33 Year Ago
8/8/2022 4:10:40 PM
Cyteir Therapeutics Q2 Loss/share $0.34 Vs. Loss $4.83 Year Ago
5/10/2022 8:22:42 AM
Wedbush Is Cutting Cyteir Therapeutics, Inc. (CYT) FY22 Estimate To -1.65 From -1.60
5/10/2022 8:22:28 AM
Wedbush Is Lowering Cyteir Therapeutics, Inc. (CYT) Q4 22 Estimate To -0.38 From -0.37
5/10/2022 8:22:14 AM
Wedbush Is Cutting Cyteir Therapeutics, Inc. (CYT) Q3 22 Estimate To -0.45 From -0.43
5/10/2022 8:22:02 AM
Wedbush Is Cutting Cyteir Therapeutics, Inc. (CYT) Q2 22 Estimate To -0.42 From -0.41
5/10/2022 8:21:30 AM
Wedbush Reiterates Cyteir Therapeutics, Inc. (CYT) At Outperform With $17 Price Target
5/5/2022 4:49:14 PM
Cyteir Therapeutics Q1 Loss/share $0.40 Vs. Loss $3.40 Year Ago
5/3/2022 9:08:15 AM
Cyteir Therapeutics Appoints Krisztina Nemenyi As SVP Of Regulatory Affairs And Quality
3/17/2022 8:26:36 AM
Wedbush Is Raising Cyteir Therapeutics, Inc. (CYT) FY22 Estimate To -1.63 From -1.93
3/17/2022 8:26:22 AM
Wedbush Is Increasing Cyteir Therapeutics, Inc. (CYT) Q4 22 Estimate To -0.40 From -0.52
3/17/2022 8:26:09 AM
Wedbush Is Raising Cyteir Therapeutics, Inc. (CYT) Q3 22 Estimate To -0.43 From -0.49
3/17/2022 8:25:55 AM
Wedbush Is Increasing Cyteir Therapeutics, Inc. (CYT) Q2 22 Estimate To -0.41 From -0.47
3/17/2022 8:25:40 AM
Wedbush Is Raising Cyteir Therapeutics, Inc. (CYT) Q1 22 Estimate To -0.39 From -0.44
3/17/2022 8:25:08 AM
Wedbush Reiterates Cyteir Therapeutics, Inc. (CYT) At Outperform With $30 Down From $40 Price Target
3/16/2022 4:12:44 PM
Cyteir Therapeutics Q4 Loss/share $0.34 Vs. Loss $2.92 Year Ago
2/8/2022 7:35:47 AM
Cyteir Announces First Patient Dosed In Phase 2 With CYT-0851 On Hematologic Malignancies And Solid Tumors
2/7/2022 7:33:56 AM
Cyteir Therapeutics Appoints John Thero To Board